Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRACLE: Polychemotherapy for Remission of Newly Diagnosed Type 2 Diabetes
NCT04271189Phase 3Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Sep 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of metformin, pioglitazone, sitagliptin, empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Azienda Ospedaliero-Universitaria di Parma. Started Sep 2020; status: completed.
02
Drugs
metforminpioglitazonesitagliptinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04271189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271189.